Skip to main content

Drug Interactions between Intelence and Reyataz

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

atazanavir etravirine

Applies to: Reyataz (atazanavir) and Intelence (etravirine)

GENERALLY AVOID: Coadministration with etravirine may decrease the plasma concentrations of atazanavir, with or without cobicistat or low-dose ritonavir as a pharmacokinetic booster. The plasma concentrations of cobicistat may also be reduced. The mechanism is etravirine induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of atazanavir, other protease inhibitors, and cobicistat. In 14 study subjects administered atazanavir 400 mg once a day with etravirine, atazanavir trough plasma concentration (Cmin) decreased significantly by approximately 47%. In 20 HIV-infected patients administered atazanavir-ritonavir (300 mg/100 mg) once a day with etravirine, the atazanavir Cmin decreased by 18%; this reduction is not considered clinically relevant. In contrast, etravirine plasma concentration is increased by the protease inhibitors, presumably due to inhibition of CYP450 3A4. Both etravirine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 50% during coadministration with atazanavir and 30% during coadministration with atazanavir-ritonavir, while etravirine Cmin increased by 58% and 26%, respectively. The systemic exposure of etravirine during coadministration with atazanavir-ritonavir was similar to exposures of etravirine observed during Phase 3 trials, where all subjects received darunavir-ritonavir as part of the background regimen.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, neither unboosted atazanavir nor atazanavir boosted with cobicistat should be prescribed in combination with etravirine. According to the product labeling for etravirine, atazanavir boosted with ritonavir may be given concomitantly with etravirine in treatment-experienced patients without dose adjustments.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Intelence (etravirine)." Ortho Biotech Inc (2008):
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Department of Health and Human Services "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultAndAdolescentGL.pdf" (2015):
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

atazanavir food

Applies to: Reyataz (atazanavir)

ADJUST DOSING INTERVAL: Administration of atazanavir with food enhances oral bioavailability and reduces pharmacokinetic variability. According to the manufacturer, administration with a light meal increased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of a single 400 mg dose of atazanavir by 57% and 70%, respectively, relative to the fasting state. Administration with a high-fat meal resulted in a mean increase of 35% in atazanavir AUC and no change in Cmax compared to fasting. The coefficient of variation of AUC and Cmax decreased by approximately one-half when given with either a light or high-fat meal compared to the fasting state.

MANAGEMENT: To ensure maximal oral absorption, atazanavir should be administered with or immediately after a meal.

References

  1. "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb (2003):

Switch to consumer interaction data

Moderate

etravirine food

Applies to: Intelence (etravirine)

ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of etravirine. The mechanism is unknown. Compared to administration following a meal, the systemic exposure (AUC) to etravirine was decreased by about 50% when the drug was administered under fasting conditions. The types of meal studied (ranging from 345 kilocalories containing 17 grams fat to 1160 kilocalories containing 70 grams fat) did not appear to make a difference with respect to impact on etravirine bioavailability.

MANAGEMENT: Etravirine should always be administered following a meal.

References

  1. "Product Information. Intelence (etravirine)." Ortho Biotech Inc (2008):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer